Financial Tearsheet

Company Overview

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, www.clinicaltrials.gov.  For additional information about Provectus, please visit the Company’s website at www.provectusbio.com or contact Allison+Partners. 

Investor Contacts

Our Contact Form Mailing Address

Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Provectus Biopharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Investor Relations Media Relations

Allison+Partners
Tom Smith, Managing Director
71 Fifth Avenue, 7th Floor
New York, NY 10003
Telephone: 646-428-0653

Allison+Partners
Todd Aydelotte,
Managing Director
71 Fifth Avenue, 7th Floor
New York, NY 10003
Telephone: 646.428.0644

Transfer Agent Investment Advisor

(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
E-mail: shareholder@broadridge.com
Telephone: +1 (877) 830-4936
Fax: +1 (215) 553-5402

Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031

Stock Performance

Today's Open 0.06
Volume 6.49 million
Day Range 0.05 - 0.07
52 Week Range 0.01 - 0.54
Bid/Ask 0.00 / 0.00
Bid/Ask Size 0 X 0
Previous Close 0.06
Market Cap 11.3 million
Shares Outstanding 212.83 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -0.14
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Mar 31, 2017 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 09, 2016 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 09, 2016 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 10, 2016 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 30, 2016 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Timothy Scott, Ph.D. , President

Eric Wachter, Ph.D. , Chief Technology Officer

John R. Glass, CPA, Interim CFO

Board of Directors

Alfred E. Smith IV , Chairman of the Board

Timothy C. Scott, Ph.D. , Board Member

Jan E. Koe , Board Member

Kelly M. McMasters, M.D., Ph.D. , Board Member

Eric Wachter, Ph.D., Board Member